Is Bonus Biogroup Ltd. (BBIXF) a Buy, Sell, or Hold?
OTC : BBIXF
Bonus Biogroup Ltd.
$0.095 USD
$0 (0.0%)
- Volume
- 10K
- Average Volume
- 218
- Market Capitalization
- $110.95M
- P/E Ratio
- -25.39
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.15
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.13
Company Overview
OTC
Shai Meretzki
Medical - Specialties
Healthcare
BBIXF
42
IL
USD
Liquidity Metrics
-1.57
0.13
0.13
0.02
0.00
Sales & Valuation
-$
0.00
-53.41
-20.24
-0.01
Profitability
-$0.0365
-$24.37M
0.00%
0.00%
667.39%
-158.60%
P/E Metrics
-25.39
-0.19
-0.19
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-29.17
1/9
-$12.24M
$15.44M
$21.1M
-$23.76M
Key Metrics (TTM)
$311.16M
0.00
-14.01
0.13
667.39%
-734.63%
-8.10%
-4.94%
0 days
Company Executives
| Name | Title |
|---|---|
| Vered Kivity | Head of Regulatory Affairs & Vice President of Clinical Affairs |
| Meital Enbar | Vice President of Finance |
| Shai Meretzki | Founder, Chief Executive Officer, President & Director |
| Tomer Bronshtein | Vice President of Innovation & Corporate Development |
| Joseph Rauch | Executive Chairman of the Board |
| Dror Ben David | Chief Operations Officer |
Poll Results
No votes yet today — be the first to share your view!
About Bonus Biogroup Ltd. (OTC:BBIXF) Stock
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanc ... ed Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Frequently Asked Questions
-
What is the current Bonus Biogroup Ltd. (BBIXF) stock price?
-
Bonus Biogroup Ltd.(OTC:BBIXF) stock price is $0.095 in the last trading session. During the trading session, BBIXF stock reached the peak price of $0.15 while $0.0003 was the lowest point it dropped to. The percentage change in BBIXF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BBIXF stock was $0.
-
BBIXF's industry and sector of operation?
-
The OTC listed BBIXF is part of Medical - Specialties industry that operates in the broader Healthcare sector.
-
Who are the executives of BBIXF?
-
Vered Kivity | Head of Regulatory Affairs & Vice President of Clinical Affairs
Meital Enbar | Vice President of Finance
Shai Meretzki | Founder, Chief Executive Officer, President & Director
Tomer Bronshtein | Vice President of Innovation & Corporate Development
Joseph Rauch | Executive Chairman of the Board -
How many employees does BBIXF have?
-
Number of BBIXF employees currently stands at 42. BBIXF operates from Matam Advanced Technology Park, Haifa, HA 3190501, IL.
-
Link for BBIXF official website?
-
Official Website of BBIXF is: https://bonus-bio.com
-
How do I contact BBIXF?
-
BBIXF could be contacted at phone #972 7 320 67104 and can also be accessed through its website. BBIXF operates from Matam Advanced Technology Park, Haifa, HA 3190501, IL.
-
How many shares of BBIXF are traded daily?
-
The average number of BBIXF shares traded daily for last 3 months was 218.
-
What is the market cap of BBIXF currently?
-
The market value of BBIXF currently stands at $110.95M with its latest stock price at $0.095